Defining Antibiotic Levels in Intensive care patients (DALI-2) protocol - A multi-national pharmacokinetic/pharmacodynamic cohort study to determine whether contemporary antibiotic dosing for critically ill patients achieves therapeutic exposures.

Start Date31 Jul 2026

Sponsor / Collaborator

Centre Hospitalier Universitaire de Nimes

ChiCTR2600120598

/ SuspendedNot Applicable

Effects of general anesthesia combined with oxybuprocaine hydrochloride eye drops on oculocardiac reflex, agitation and pain during recovery period during strabismus surgery in children

Start Date23 Mar 2026

Sponsor / Collaborator

Ningxia Hui Autonomous Region People's Hospital

CTR20252513

/ Active, not recruitingNot Applicable

妥布霉素吸入溶液长期给药方案治疗支气管扩张症伴铜绿假单胞菌感染患者中血清及肺内药物浓度及药代动力学/药效学与疗效评价研究

[Translation] Study on serum and lung drug concentrations, pharmacokinetics/pharmacodynamics and efficacy evaluation of long-term administration of tobramycin inhalation solution in the treatment of bronchiectasis patients with Pseudomonas aeruginosa infection

1) 评价妥布霉素吸入溶液在支气管扩张症（支扩症）伴铜绿假单胞菌（PA）感染患者中多次用药后在肺上皮衬液（ELF）和血清中的药物浓度及ELF到血液的渗透性； 2) 评价妥布霉素吸入溶液长疗程（12周）给药方案，治疗支扩症伴PA感染患者的细菌学指标变化； 3) 研究妥布霉素吸入溶液在支扩症伴PA感染患者中多次用药后的药代动力学（PK）/药效学（PD）与疗效相关性。

[Translation]

1) To evaluate the drug concentration of tobramycin inhalation solution in pulmonary epithelial lining fluid (ELF) and serum and the permeability of ELF to blood after multiple administration in patients with bronchiectasis (bronchiectasis) and Pseudomonas aeruginosa (PA) infection; 2) To evaluate the long-term (12-week) dosing regimen of tobramycin inhalation solution to treat the changes in bacteriological indicators in patients with bronchiectasis and PA infection; 3) To study the pharmacokinetics (PK)/pharmacodynamics (PD) and efficacy correlation of tobramycin inhalation solution in patients with bronchiectasis and PA infection after multiple administration.

Start Date10 Oct 2025

Sponsor / Collaborator

Healthy Yuan Haibin Pharmaceutical Co., Ltd.

[+1]

100 Clinical Results associated with Tobramycin

100 Translational Medicine associated with Tobramycin

100 Patents (Medical) associated with Tobramycin

11,391

Literatures (Medical) associated with Tobramycin

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Comparison the effect of Curcumin and methanolic extracts of Fraxinus excelsior L. and glycyrrhiza glabra L. on the expression of MexCD-OprJ and MexEF-OprN efflux pumps in multidrug resistant Pseudomonas aeruginosa clinical isolates

Article

Author: Goli, Hamid Reza ; Gholami, Mehrdad ; Jamal, Zeynab ; Ebrahimzadeh, Mohammad Ali

BACKGROUND:

Pseudomonas aeruginosa is a multidrug-resistant (MDR) pathogen, and efflux pumps such as MexCD-OprJ and MexEF-OprN play a key role in its antibiotic resistance. This study evaluated the putative effects of curcumin and methanolic extracts of F. excelsior L. and G. glabra L. on the expression of these efflux pumps, as well as their role in mediating antibiotic resistance.

METHODS AND RESULTS:

In this study, MDR P. aeruginosa clinical strains were used to determine the minimum inhibitory concentrations (MICs) of tobramycin and ciprofloxacin in the presence and absence of curcumin and selected plant extracts (F. excelsior L. and G. glabra L.) and curcumin. Real-time PCR was used to assess changes in efflux pump gene expression in tested strains. A significant positive correlation was identified between resistance to the tested antibiotics and increased expression of MexCD-OprJ and MexEF-OprN, as determined by Spearman's rank correlation using SPSS (p < 0.05). Treatment with the extracts, individually and in combination, resulted in a reduction in the expression levels of both efflux genes (p < 0.05), with the combined treatment showing the greatest effect. These findings were supported by colony count and turbidity assays, as evidenced by > 80% reduction in viable counts and decreased turbidity in treated groups.

CONCLUSION:

Overexpression of MexCD-OprJ and MexEF-OprN is a key factor contributing to MDR in P. aeruginosa. Treatment with curcumin, F. excelsior L. and G. glabra L. extracts-especially in combination, suggesting potential for suppression of efflux gene expression and enhanced antibiotic efficacy.

01 Dec 2026·FUNCTIONAL & INTEGRATIVE GENOMICS

An integrated computational-experimental approach identifies Malate Synthase G as therapeutic target to disrupt carbon metabolism in chronic Pseudomonas aeruginosa infection

Article

Author: Wang, Rui ; Mo, Jingyi ; Xu, Jun ; Chen, Geping ; Chen, Wenying ; Zhou, Haochuan ; Tan, Qiutong

Pseudomonas aeruginosa is a leading cause of nosocomial infections, particularly in individuals with a compromised immune system. Due to its strong adaptive ability, P. aeruginosa tends to develop antibiotic resistance and establish chronic infection, making its eradication through traditional antibiotics challenging. Thus, the development of novel therapeutic targets and corresponding inhibitors is urgently required. We conducted bioinformatics analyses of gene-chip datasets (GSE10362, GSE21966) of P. aeruginosa from patients with cystic fibrosis (CF) in the Gene Expression Omnibus (GEO) database, ranging from early to late stages of infection. Differentially expressed gene (DEG) analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment, and Weighted Gene Co-expression Network Analysis (WGCNA) were performed to identify key functional DEGs. Among these genes, candidate genes were refined using three machine learning algorithms: LASSO regression, random forest (RF), and support vector machine (SVM). Using this integrated approach and published reports, target gene was identified consequently. With reported inhibitors, a structure-based virtual screening model against the target protein was established to screen inhibitors from an FDA-approved drug library. Screened hits were experimentally validated through in vitro MIC and checkerboard broth microdilution assays to determine their antibacterial activity and the synergistic effect of tobramycin (TOB) and amikacin (AMK). Enzyme activity was measured to evaluate target protein inhibition. Transcriptome sequencing analysis was performed to explain the effect of target inhibition and reveal the possible mechanism of inhibition. We identified 210 upregulated genes in the late stage of infection. KEGG functional enrichment demonstrated that the up-regulated genes were mainly enriched in metabolic pathways. Eight metabolism-related key DEGs were obtained by the intersection of genes from metabolic pathways and genes from the key module of WGCNA. Machine learning algorithms (LASSO, RF, and SVM) and literature investigation results identified glcB, which encodes malate synthase G (MS), as a therapeutic target for developing inhibitors. In virtual screening, we formulated four rules for a screening model based on the docking results, and finally identified three FDA-approved drugs prednisolone, dienogest and carbinoxamine maleate salt (CAR) as candidates. In vitro MIC assay and checkerboard assay suggested that CAR had an antibacterial effect with a concentration-dependent trend and could enhance the effect of tobramycin and amikacin. Consistent with MIC assay, the inhibition rate in MS activity assay showed a concentration-dependent trend. Transcriptome sequencing analysis showed that carbon metabolism was remodeled when MS was inhibited, thus impairing the growth of P. aeruginosa, and the synergistic effect with TOB and AMK may be explained by the impaired ability to combat oxidative stress. This study identified and validated drug target glcB (encodes MS) and potential inhibitor CAR in treating chronic P. aeruginosa infection based on an integrated method of bioinformatics, virtual screening, and in vitro experiments.

01 Nov 2026·COLLOIDS AND SURFACES B-BIOINTERFACES

Inflammation-responsive liposomes co-delivering tobramycin and nitric oxide for overcoming mucus barriers against MRSA pneumonia

Article

Author: Feng, Jia-Wen ; Gui, Ping ; Ou, Jun-Ge ; Wang, Yue ; Wang, Guan-Hai ; Ma, Dong ; Zhang, Jia-Qi

Methicillin-resistant Staphylococcus aureus (MRSA) pneumonia remains difficult to treat because mucus-associated transport barriers, biofilm formation, and excessive inflammation jointly limit therapeutic efficacy. Here, we developed a nebulizable chitosan-coated liposomal co-delivery system, LC@Tob/NO, for pulmonary treatment of MRSA pneumonia. The formulation integrates liposome-mediated pulmonary delivery, chitosan-associated surface reconstruction, tobramycin-mediated antibacterial activity, and mildly acidic inflammation-associated NO release from DETA/NO, thereby enabling localized Tob/NO co-loading for MRSA pneumonia therapy. LC@Tob/NO exhibited favorable physicochemical characteristics, enhanced transport through an artificial mucus matrix, and effective pulmonary deposition after nebulization. In vitro, the formulation showed potent antibacterial and antibiofilm activities against MRSA, while also attenuating oxidative stress and pro-inflammatory activation in macrophages. In a murine MRSA pneumonia model, nebulized LC@Tob/NO markedly reduced bacterial burden, alleviated lung edema and tissue injury, and suppressed inflammatory responses, with acceptable systemic biosafety. Supportive lung transcriptomic analysis suggested treatment-associated changes in immune and inflammatory pathways that were consistent with the observed bacterial clearance, cytokine reduction, and histological improvement. Collectively, LC@Tob/NO represents a promising inhalable biomaterial-based therapeutic strategy for MRSA pneumonia by integrating antibacterial activity with microenvironment regulation.

News (Medical) associated with Tobramycin

02 Sep 2026

·ritedose.com

One Size No Longer Fits All in Pharmaceutical Manufacturing

Specialized CDMOs combine precision, agility and scale to meet the evolving needs of complex pharmaceutical manufacturing. This is production on purpose. The drugs that define the future of pharmaceutical manufacturing are not the ones that serve the largest populations. They are the ones that are hardest to get right. Getting them right requires a manufacturer that combines the precision of specialized production with the scale to serve millions of patients reliably. Enter a new type of manufacturing. According to DrugPatentWatch, 85 percent of the Contract Development and Manufacturing Organization (CDMO) market is in specialized, precision mid-market companies. This sector of the market depends on specialized, targeted CDMOs for clinical supply chain resilience, reliable manufacturing, and regulatory compliance. For either smaller developers or those in the earlier stages of drug manufacturing, specialized CDMOs are generally more accessible. These types of CDMOs are usually more flexible, can help with troubleshooting, and can make changes much more quickly than very large manufacturers who have set processes and procedures. Specialized manufacturers usually specialize in complex, lower-volume drug development and production. Drugs include sterile injectables, ophthalmic solutions, or any product that must follow specific manufacturing methods. These are often biologicals but also include small molecule drugs that require sterile fill-finish or aseptic processing, such as preservative-free ophthalmic treatments. Targeted CDMOs are providing more agile, focused approaches to manufacturing as the entire pharmaceutical and biotech industries move away from the “one size fits all” model of drug development While Ritedose is the largest U.S.-based CDMO using sterile, precision-driven Blow-Fill-Seal (BFS) technology to manufacture drugs, we are prioritizing our ability to retain agility and adapt to new clients and drug classes, as well as economic and geopolitical conditions. These agile processes enable the development of valuable specialized drugs and aseptic processing of these more targeted products. For example, earlier this year Ritedose announced we entered a partnership with TenPoint Therapeutics Ltd., to manufacture its new drug Yuvezzi™, the first (and only) dual-agent FDA-approved eye drop to treat presbyopia, an eye condition (impaired closeup vision) affecting 128 million Americans. Ophthalmic drugs must be manufactured under strict aseptic conditions because of the unique environment of the eye. Meanwhile, we are continuing with our innovative, agile and reliable manufacturing of respiratory drugs for various diseases, including Ohtuvayre®, a first-in-class, steroid-free maintenance treatment for COPD in adults, and generic Tobramycin, which treats infections of Pseudomonas aeruginosa, a common bacterial infection among cystic fibrosis patients. It’s a common misconception that targeted, specialized manufacturing addresses only rare diseases or small subsets of more common ones. As noted, presbyopia affects more than one hundred million Americans, and COPD affects 11 million in the United States alone. These are significant products that could potentially yield billions in revenues for their makers. And their manufacturing needs to be commercially viable. There’s no room for bloat. Processes must be efficient and intensified, with greater continuity. Precision-driven processes also plays a strong role, speeding up processing while reducing errors and the risk of contamination. It’s also necessary to optimize the production of starting ingredients, reliably sourcing every part of the supply chain, and using these ingredients and processes in the most cost-effective (yet safe and dependable) way possible. CDMOs can achieve viability in several ways, using their agility to create a process that works for the manufacturer, drug sponsor, providers and patients. Firms have looked at making manufacturing more product-agnostic so that processes can be used over a wider range of products. They have also looked at repurposing certain materials to manage costs. Still others, including Ritedose, have invested in digital innovations and advanced technologies, including artificial intelligence/large language models, to increase efficiency. One important fact that the move away from mass-market drug development has revealed is that historically, the drug-manufacturing industry is not very standardized. Suppliers have been used to working in silos, and manufacturers have services, technologies and products from a wide range of vendors. There is now clearly a need to make product transfers seamless, by integrating equipment, data and software. The future of pharmaceutical manufacturing will need to be flexible, adaptable, efficient and above all have quality built into every step. Building relationships and trust is key to how we operate at Ritedose. We have a 25-year history of reliable, safe and on-time manufacturing with our customers. To achieve this level of trust, it’s important to make sure a CDMO’s strengths sync with what you need for your current stages of drug development. Here, we work with our drug-manufacturing customers to ensure we make the right mix together. Specialized CDMOs combine precision, agility and scale to meet the evolving needs of complex pharmaceutical manufacturing. This is production on purpose.

14 Jul 2026

·www.biospace.com

Sound Pharma completes enrollment of Open Label Phase 3 study of SPI-1005 in Meniere’s Disease

SEATTLE--(BUSINESS WIRE)--Sound Pharmaceuticals is pleased to announce that it completed enrollment of its second Phase 3 open label study of SPI-1005 for the Treatment of Meniere’s Disease (MD). SPI-1005, a novel oral anti-inflammatory drug, received Breakthrough Therapy Designation (BTD) in late 2025. MD is a complex inner ear disease that involves low to mid frequency hearing loss, tinnitus, vertigo, and dizziness. SPI-1005 is the first drug to receive BTD for MD and for the treatment of sensorineural hearing loss, the most prevalent disease involving the nervous system. Sensorineural hearing loss is documented using pure-tone audiometry (PTA) and speech discrimination testing including the words-in-noise (WIN) test that are the gold standards for diagnosing and grading hearing loss and other auditory dysfunction. “We look forward to advancing SPI-1005 as the first approved treatment for Meniere’s later this year and early next year,” said Dr. Jonathan Kil, Co-Founder and CEO. This open label Phase 3 study was performed to accrue additional safety data to allow for chronic daily dosing of SPI-1005 and enrolled 191 participants at 9 US sites in 8 months’ time. The four MD trials have now enrolled a total of 578 adults with probable or definite Meniere’s. To our knowledge, this represents the greatest number of MD participants enrolled in an investigational new drug trial over the last 10 years. SPI-1005 trials have also achieved favorable safety and efficacy results in a Phase 2 RCT in acute noise-induced hearing loss, and a Phase 2 RCT in aminoglycoside-induced ototoxicity. About SPI-1005 SPI-1005, an oral capsule taken twice daily contains ebselen, a new chemical entity that mimics and induces glutathione peroxidase (GPx) activity. GPx1 is a critical enzyme that repairs injured and aging cells in the inner ear, retina, prefrontal cortex of brain, lung, and kidney, and is reduced during and after exposure to environmental insults such as noise, ototoxic drugs, or aging. Consequently, neuroinflammation can progress throughout the peripheral and central nervous system leading to neurodegeneration and/or maladaptive plasticity. SPI-1005 is being developed for several neurotologic indications beyond MD including, noise-induced hearing loss and tinnitus, and two types of ototoxicity (hearing loss, tinnitus, dizziness, or vertigo) caused by aminoglycoside antibiotics (such as tobramycin or amikacin) or platinum-based chemotherapy (such as cisplatin or carboplatin). To date, no significant drug-drug interactions have been observed across multiple study populations including MD, cystic fibrosis, bipolar mania, and treatment-resistant depression. Fifteen ongoing and completed SPI-1005 trials have enrolled more than 980 patients with 200+ more enrolled patients anticipated over the next year. About Sound Pharmaceuticals Sound Pharma is a private biotechnology company studying SPI-1005 under five active INDs involving several neurotologic indications. Details of the SPI-1005 clinical trials can be viewed online at or . Please contact info@soundpharma.com for further information. Contacts Please contact info@soundpharma.com for further information.

19 May 2026

·www.biospace.com

Halia Therapeutics Appoints Gary Sabin as Executive Chairman and Adds Three Independent Directors to Board

Industry leaders join at a pivotal moment as company advances HT-6184 toward a pivotal trial in MDS and prepares Phase 2a initiation for HT-4253 in Alzheimer's disease LEHI, Utah , May 19, 2026 /PRNewswire/ -- Halia Therapeutics, Inc., The Genetic Resilience Company™ , a clinical-stage biopharmaceutical company advancing first-in-class inflammation therapies anchored in protective human genetics, today announced the appointment of Gary Sabin as Executive Chairman of the Board of Directors. Mr. Sabin has been a member of Halia's Board of Directors since January 2025. The company also announced the additions of Preston Campbell, MD, David Checketts, and Mary Beckerle, PhD, as independent members of the board. The expanded board joins Halia at a defining moment for the company, as it advances HT-6184 toward pivotal development in lower-risk myelodysplastic syndromes and continues to build its broader pipeline across inflammation-driven diseases. Earlier this month, Halia announced final Phase 2 data for HT-6184 in lower-risk MDS, as well as the appointment of Han Myint, MD, FACP, as Chief Medical Officer, further strengthening the company's clinical and leadership foundation for its next phase of growth. "We are pleased to formally expand Gary's leadership role to Executive Chairman and to welcome Preston, David, and Mary to the board," said David J. Bearss, PhD, Chief Executive Officer of Halia Therapeutics. "Since joining our board in January 2025, Gary has been a highly engaged strategic partner, and his experience in capital markets, governance, and company-building has already contributed meaningfully to Halia's growth. Together with the additions of Preston, David, and Mary and following the recent advancement of our lower-risk MDS program and appointment of Dr. Han Myint as Chief Medical Officer, we are continuing to strengthen the leadership, scientific and strategic capabilities needed to advance HT-6184 toward pivotal development, expand our pipeline and support the company's next phase of growth, financing and partnering." "Halia's platform is the rare combination of a clear, genetically validated mechanism and clinical data that already supports its potential," said Gary Sabin, Executive Chairman. "Over the past year, I have had the opportunity to work closely with David, the leadership team, and the board, and I am excited to deepen that engagement as Executive Chairman, while helping build the company for long-term success." About the New Directors Gary B. Sabin — Executive Chairman Gary B. Sabin joined Halia's Board of Directors in January 2025 and now serves as Executive Chairman, bringing more than four decades of leadership in capital markets and asset-intensive businesses. He previously served as Chairman and CEO of Excel Realty Trust and Excel Trust, both of which were listed on the New York Stock Exchange, and is founder and chairman of Sabin Holdings, an Asia-Pacific-focused real estate investment firm. He has served on the boards of public companies including CareTrust REIT and Extra Space Storage and nonprofits including the Cystic Fibrosis Foundation, where he served for 20 years, including as Vice Chairman of the Board and Chairman of the Executive Committee. During his tenure, the Foundation was instrumental in facilitating FDA approval of several new therapies, including the disease-modifying drug Trikafta, as well as Tobi, Pulmozyme, Symdeko, Orkambi, Kalydeco, and Cayston. He holds a Master's in Management from Stanford University (Sloan Fellow) and a BS in Finance from Brigham Young University. At Halia, Mr. Sabin brings capital markets perspective, public-company governance experience, and executive discipline, and is working closely with leadership on financing, strategy, and growth. Preston W. Campbell III, MD Preston W. Campbell III, MD, is a physician-executive and former President and CEO of the Cystic Fibrosis Foundation (2015–2019). Dr. Campbell brings to Halia clinical development, patient-registry, and translational medicine experience aligned with the company's genetically informed pipeline. Over more than two decades at the Foundation, including as EVP for Medical Affairs, he oversaw research, drug discovery and development, the accredited care-center network, and the national patient registry, infrastructure behind many of the pivotal studies in cystic fibrosis. He trained in pediatrics and pediatric pulmonology at Vanderbilt and has more than 25 years of clinical experience in cystic fibrosis at institutions, including Johns Hopkins. David W. Checketts David W. Checketts is a veteran chief executive and investor with more than four decades of experience across sports, media, entertainment, and private equity. Mr. Checketts adds brand-building, governance, and capital formation experience as Halia transitions to a growth-stage organization. He became president and general manager of the Utah Jazz at age 28, then the youngest chief executive in NBA history, and later served as President and CEO of Madison Square Garden, overseeing its sports franchises and media networks. He subsequently served as Chairman and CEO of Legends Hospitality, managing partner of Checketts Partners Investment Management, and was a founding board member of JetBlue Airways. Mary C. Beckerle, PhD Mary C. Beckerle, PhD, is a cancer biologist and scientific leader who served as CEO of Huntsman Cancer Institute (2006–2025). She is Distinguished Professor of Biology and Oncological Sciences at the University of Utah. She joined the University of Utah faculty in 1986 and is recognized for pioneering research on cell adhesion, migration, invasion, and metastasis. She serves on the boards of Johnson & Johnson and Exelixis, is an elected member of the National Academy of Sciences, and has served on the Advisory Committee to the Director of the National Institutes of Health. The new directors join existing board members Keoni Kauwe, PhD, Co-founder, and David J. Bearss, PhD, Chief Executive Officer. About Halia Therapeutics Halia Therapeutics is a clinical-stage platform company focused on inflammation biology. The company's platform is anchored in protective human genetics that identified the LRRK2 -> RAB10 -> NEK7 -> NLRP3 axis as a source of human disease resilience. Halia is translating that biology into a pipeline of first-in-class programs, including HT-6184 in lower-risk myelodysplastic syndromes and additional hematologic indications, HT-4253 for Alzheimer's disease in APOE4 carriers, HT-6105 targeting residual inflammatory risk via hsCRP reduction, and HT-10068 for metabolic disease. To learn more, visit haliatx.com . Contacts Taylor Avei Director of Business Development Halia Therapeutics tavei@haliatx.com Investor Relations: Leigh Salvo New Street Investor Relations leigh@newstreetir.com View original content to download multimedia: SOURCE Halia Therapeutics

Executive ChangePhase 2Drug Approval

100 Deals associated with Tobramycin

External Link

KEGG	Wiki	ATC	Drug Bank
D00063	Tobramycin	S01AA12 J01GB01	DB00684

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bronchiectasis	China	Joincare Pharmaceutical Group Industry Co., Ltd.	11 Oct 2022
Cystic Fibrosis	Japan	Viatris Healthcare GK	28 Sep 2012
Cystic Fibrosis	Japan	Viatris Pharmaceutical GK	28 Sep 2012
Infectious Lung Disorder	European Union	Viatris Healthcare (Pty) Ltd.	20 Jul 2011
Infectious Lung Disorder	Iceland	Viatris Healthcare (Pty) Ltd.	20 Jul 2011
Infectious Lung Disorder	Liechtenstein	Viatris Healthcare (Pty) Ltd.	20 Jul 2011
Infectious Lung Disorder	Norway	Viatris Healthcare (Pty) Ltd.	20 Jul 2011
Infectious Lung Disorder	United Kingdom	Viatris Products Ltd.	20 Jul 2011
Pseudomonas Infections	United States	Viatris Specialty LLC	22 Dec 1997
Acute Bronchitis	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Cystitis	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Hemorrhagic Septicemia	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Peritonitis	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Pneumonia	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Pyelonephritis	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Pyoderma	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Secondary infection	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Blepharitis	Japan	Nitto Medic Co., Ltd.	07 Dec 1981
Conjunctivitis	Japan	Nitto Medic Co., Ltd.	07 Dec 1981
Corneal Ulcer	Japan	Nitto Medic Co., Ltd.	07 Dec 1981

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cataract	Phase 3	United States	Bausch & Lomb, Inc.	01 Feb 2009
Pseudomonas aeruginosa infection	Phase 3	Lithuania	Novartis Pharma Services AG	19 Sep 2005
Eye Infections	Phase 3	United States	Bausch & Lomb, Inc.	01 Jul 2005
Postoperative Complications	Phase 3	United States	Bausch & Lomb, Inc.	01 Jul 2005
Non-cystic fibrosis bronchiectasis	Phase 2	Belgium	Novartis Pharmaceuticals Corp.	08 Feb 2017
Non-cystic fibrosis bronchiectasis	Phase 2	France	Novartis Pharmaceuticals Corp.	08 Feb 2017
Non-cystic fibrosis bronchiectasis	Phase 2	Germany	Novartis Pharmaceuticals Corp.	08 Feb 2017
Non-cystic fibrosis bronchiectasis	Phase 2	Italy	Novartis Pharmaceuticals Corp.	08 Feb 2017
Non-cystic fibrosis bronchiectasis	Phase 2	Spain	Novartis Pharmaceuticals Corp.	08 Feb 2017
Non-cystic fibrosis bronchiectasis	Phase 2	United Kingdom	Novartis Pharmaceuticals Corp.	08 Feb 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05865743 (PERSuaDER, Pubmed \| Trials)	Phase 3	Esophageal Carcinoma	854	SDD prophylaxis	rcdvvudryi(qxcnpuqdjh) = peoowxzxuy hniqoxndjs (aadlsdaopo )	Positive	04 Dec 2025
ERS2023	Not Applicable	Bronchiectasis	13	Tobramycin inhalation solution (TIS) 170 mg	wnggxfodgq(oulwqsjksg) = one patient odhvreqdnk (dyaurevtlj ) View more	Positive	09 Sep 2023
NCT03705962 (CTgov)	Phase 3	Fractures, Open \| Infectious Diseases	11	Tobramycin (Antibiotic)	moklfjxmrb = gpnvqkjddp sqvholdisu (tanqmejohp, yzhzsvjjbp - qhppjnueda) View more	-	15 Jun 2023
				Placebo: normal saline (Normal Saline)	moklfjxmrb = wnatifegzo sqvholdisu (tanqmejohp, pmowauirci - rsmyfcorcs) View more
NCT02478710 (AAINTVAP, CTgov)	Phase 4	Pneumonia, Ventilator-Associated	16	Aerosolized Placebo (Aerosolized Placebo)	peqwvgdvid(byctcxlqvz) = sjsjazkbza qdjirgrkhg (swzfccmpxj, mzbymgmmfy - qpmrgetehx) View more	-	22 May 2023
				Tobramycin+Vancomycin (Aerosolized Tobramycin or Vancomycin)	peqwvgdvid(byctcxlqvz) = xyzrwufjxn qdjirgrkhg (swzfccmpxj, fxrupkasha - odoihtsjof) View more
NCT02657473 (The BATTLE study, Pubmed \| Respir Res)	Phase 2/3	Non-cystic fibrosis bronchiectasis Maintenance	58	Tobramycin inhalation solution (TIS)	lzzsgmidau(miwwefhjik): RR = 0.74 (95% CI, 0.49 - 1.14), P-Value = 0.15	-	03 Dec 2022
				Placebo
NCT02918409 (CTgov)	Phase 4	Cystic Fibrosis	51	Colistin (Standard Colistin Arm)	icbooxctiv(zjoxcknpkv) = wgvmhyoqdi sfgootioon (nxfhohanmb, 9.5) View more	-	06 Oct 2022
				Colistin (Modified Colistin Arm)	icbooxctiv(zjoxcknpkv) = kjrotpbkmt sfgootioon (nxfhohanmb, 3.0) View more
NCT03673956 (CTgov)	Phase 1/2	Chronic sinusitis	19	Tobramycin (Tobramycin Topical Antibiotic Nasal Saline Rinse)	cvlunzbynq = dewcrvynop ktchjwtmed (sbkgxxttbq, reumtgwcbs - hoxkxohnjx) View more	-	20 Apr 2022
				levofloxacin (Levofloxacin Topical Antibiotic Nasal Saline Rinse)	cvlunzbynq = hsahpzsouo ktchjwtmed (sbkgxxttbq, rjvvqxlvas - aiobcqkmcj) View more
NCT04297631 (CTgov)	Phase 4	-	20	Tobramycin+Vancomycin (Intraarticular Concentrations of Tobramycin and Vancomycin)	gerlxkwyzv(tfhbunsinj) = okrerxbqha friruamogp (nmfnyqgjta, rzsgdzsyab - bxppljbdpo) View more	-	05 Oct 2021
				Tobramycin+Vancomycin (Vancomycin and Tobramycin Serum Concentration)	gkwrkpkoya(sapbmcyqzz) = jvxwlurkjl vwmdzqwwrs (ttkifkxxqw, thrvizkmpt - mwqcthbefu) View more
NCT00982930 (CTgov)	Phase 3	Pseudomonas aeruginosa infection \| Cystic Fibrosis	55	Tobramycin	saxljshzjn = nrvdbdpfoj xkgmvshqwh (sxjcfspvoq, kyxwiqggof - lqvwgdkcst) View more	-	02 Jun 2021
NCT01069705 (CTgov)	Phase 3	Pseudomonas Infections \| Pseudomonas aeruginosa infection \| Cystic Fibrosis ... View more	49	Tobramycin inhalation powder	jswxkwhuld = tmedhhcryy ycxkagbpmj (uiyaixevob, pyfevrymmr - sywacngmex) View more	-	02 Jun 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis